A case of COVID‐19‐associated C‐ANCA vasculitis, was successfully treated with rituximab therapy
Michael Filoramo, Renish Contractor, Deepak Chandramohan, Prabhat Singh, Nihar Jena, Prathap Kumar Simhadri
TL;DR
A patient with a rare immune condition linked to COVID-19 was successfully treated with a combination of steroids and rituximab.
Contribution
The paper presents a successful treatment case of C-ANCA vasculitis associated with COVID-19 using rituximab.
Findings
The patient was treated with steroids and rituximab for C-ANCA vasculitis linked to COVID-19.
The treatment was effective without significant adverse reactions.
This case adds to the limited evidence on managing this rare condition.
Abstract
Both C‐anti‐neutrophil cytoplasmic antibody (ANCA) and P‐ANCA vasculitis were reported to be associated with COVID‐19 infection. The ideal management of COVID‐19‐associated ANCA vasculitis is unclear, as the experiences were limited to case reports. We presented a case of COVID‐19‐associated C‐ANCA vasculitis, successfully treated with steroids and rituximab therapy without any significant adverse reactions.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsVasculitis and related conditions · Heparin-Induced Thrombocytopenia and Thrombosis · Otitis Media and Relapsing Polychondritis